The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis

References

• Coresh J, Byrd-Holt D, Astor BC et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005;16: 180–8
   Google Scholar
• Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801–8
   PubMed Web of Science ®Google Scholar
• Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658–66
   PubMed Web of Science ®Google Scholar
• Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504–10
   Google Scholar
• De Santo RM, Bartiromo M, Cesare MC, et al. Sleeping disorders in early chronic kidney disease. Semin Nephrol 2006;26:64–7
   PubMed Web of Science ®Google Scholar
• Lingren C. New survey provides insight into CKD, exhaustion, anemia. Nephrol News Issues 2003;17:29–31
   PubMedGoogle Scholar
• Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955–62
   Google Scholar
• Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18\(Suppl 2):ii2–6
   Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–305
   PubMed Web of Science ®Google Scholar
• Jurkovitz CT, Abramson JL, Vaccarino LV, et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003;14:2919–25
   PubMed Web of Science ®Google Scholar
• Walters BA, Hays RD, Spritzer KL, et al. Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. Am J Kidney Dis 2002;40:1185–94
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471–530
   PubMed Web of Science ®Google Scholar
• McClellan WM, Jurkovitz C, Abramson J. The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease. Eur J Clin Invest 2005;35(Suppl 3): 58–65
   Google Scholar
• Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol Dial Transplant 2002;17(Suppl 11):44–6
   PubMed Web of Science ®Google Scholar
• US Renal Data System, USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007
   Google Scholar
• Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548–54
   PubMed Web of Science ®Google Scholar
• Deicher R, Horl WH. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs 2004;64:499–509
   PubMed Web of Science ®Google Scholar
• Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414–21
   PubMed Web of Science ®Google Scholar
• Padhi D, Ni L, Cooke B, et al. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006;45:503–10
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290–9
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Silver MR, Reed JE, et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 2006;260: 577–85
   PubMed Web of Science ®Google Scholar
• Disney A, Jersey PD, Kirkland G, et al. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study. Nephrology (Carlton) 2007;12:95–101
   PubMed Web of Science ®Google Scholar
• Hertel J, Locay H, Scarlata D, et al. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Am J Nephrol 2006;26:149–56
   PubMed Web of Science ®Google Scholar
• Hertel JE, Locay HR, Scarlata DS, et al. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin Proc 2006;81:1188–94
   PubMed Web of Science ®Google Scholar
• Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005;63:327–34
   PubMed Web of Science ®Google Scholar
• Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003;23: 106–11
   PubMed Web of Science ®Google Scholar
• Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24:453–60
   PubMed Web of Science ®Google Scholar
• Alexander M, Kewalramani R, Agodoa I, et al. Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin 2007
   Google Scholar
• Cella D, Webster K. Linking outcomes management to quality-of-life measurement. Oncology (Williston Park) 1997;11:232–5
   PubMedGoogle Scholar
• Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant 2000;(15 Suppl 3):23–8
   Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70
   Google Scholar
• Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–33
   PubMed Web of Science ®Google Scholar
• Hays RD, Kallich JD, Mapes DL, et al. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994;3:329–38
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI Clinical Practice Guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:S182–238
   PubMed Web of Science ®Google Scholar
• Cersosimo RJ, Jacobson DR. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann Pharmacother 2006;40:58–65; quiz 169–70
   Google Scholar
• Kimmel PL, Greer JW, Milam RA, et al. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998. Semin Nephrol 2000;20: 335–44
   Google Scholar
• Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30: 473–83
   Google Scholar
• Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15:141–55
   PubMed Web of Science ®Google Scholar
• Richter A, Anton SE, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307–35
   PubMed Web of Science ®Google Scholar
• Moore T, Chookie S. Extended dosing of darbepoetin alfa in patients with chronic kidney disease not on dialysis: a review of recent data. Nephrol Nurs J 2005;32:399–407
   PubMedGoogle Scholar